Abstract

The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples across 33 cancer types using TCGA RNA-seq data. Compared with matched normal tissues, global enhancer activation was observed in most cancers. Across cancer types, global enhancer activity was positively associated with aneuploidy, but not mutation load, suggesting a hypothesis centered on “chromatin-state” to explain their interplay. Integrating eQTL, mRNA co-expression, and Hi-C data analysis, we developed a computational method to infer causal enhancer-gene interactions, revealing enhancers of clinically actionable genes. Having identified an enhancer ∼140 kb downstream of PD-L1, a major immunotherapy target, we validated it experimentally. This study provides a systematic view of enhancer activity in diverse tumor contexts and suggests the clinical implications of enhancers. Causal enhancer-target-gene relationships are inferred from a systematic analysis of 33 cancer types.

LanguageEnglish (US)
Pages386-399.e12
JournalCell
Volume173
Issue number2
DOIs
StatePublished - Apr 5 2018

Fingerprint

Genes
Tumors
Neoplasms
Computational methods
Chromatin
Chemical activation
RNA
Tissue
Messenger RNA
Aneuploidy
DNA
Immunotherapy
Genome
Mutation

Keywords

  • PD-L1 expression
  • The Cancer Genome Atlas
  • aneuploidy
  • chromatin state
  • enhancer expression
  • mutation burden
  • pan-cancer analysis
  • prognostic markers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. / The Cancer Genome Atlas Research Network.

In: Cell, Vol. 173, No. 2, 05.04.2018, p. 386-399.e12.

Research output: Contribution to journalArticle

The Cancer Genome Atlas Research Network 2018, 'A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples' Cell, vol. 173, no. 2, pp. 386-399.e12. https://doi.org/10.1016/j.cell.2018.03.027
The Cancer Genome Atlas Research Network. / A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. In: Cell. 2018 ; Vol. 173, No. 2. pp. 386-399.e12.
@article{3a5dda78883f4f289d78b4ecba9db433,
title = "A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples",
abstract = "The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples across 33 cancer types using TCGA RNA-seq data. Compared with matched normal tissues, global enhancer activation was observed in most cancers. Across cancer types, global enhancer activity was positively associated with aneuploidy, but not mutation load, suggesting a hypothesis centered on “chromatin-state” to explain their interplay. Integrating eQTL, mRNA co-expression, and Hi-C data analysis, we developed a computational method to infer causal enhancer-gene interactions, revealing enhancers of clinically actionable genes. Having identified an enhancer ∼140 kb downstream of PD-L1, a major immunotherapy target, we validated it experimentally. This study provides a systematic view of enhancer activity in diverse tumor contexts and suggests the clinical implications of enhancers. Causal enhancer-target-gene relationships are inferred from a systematic analysis of 33 cancer types.",
keywords = "PD-L1 expression, The Cancer Genome Atlas, aneuploidy, chromatin state, enhancer expression, mutation burden, pan-cancer analysis, prognostic markers",
author = "{The Cancer Genome Atlas Research Network} and Han Chen and Han Chen and Xinxin Peng and Xinxin Peng and Weinstein, {John N.} and Weinstein, {John N} and Demchok, {John A.} and Ina Felau and Melpomeni Kasapi and Ferguson, {Martin L.} and Hutter, {Carolyn M.} and Sofia, {Heidi J.} and Roy Tarnuzzer and Zhining Wang and Liming Yang and Zenklusen, {Jean C.} and Yuexin Liu and Rehan Akbani and Broom, {Bradley McIntosh} and Kanchi, {Rupa Sridevi} and Anil Korkut and Jun Li and Shiyun Ling and Yiling Lu and Mills, {Gordon B} and {Uppore Kukkillaya}, {Arvind Rao} and Xiuping Liu and Linghua Wang and Carvalho, {Andr{\'e} L.} and Fregnani, {Jos{\'e} Humberto T. G.} and Scapulatempo, {Cristovam Neto} and Ajani, {Jaffer A} and Behrens, {Maria del Carmen} and Russell Broaddus and Czerniak, {Bogdan A} and Bita Esmaeli and Junya Fujimoto and Gershenwald, {Jeffrey E} and Alexander Lazar and Logothetis, {Christopher J} and Funda Meric-Bernstam and Cesar Moran and Ramondetta, {Lois M} and Sood, {Anil K} and Pheroze Tamboli and Timothy Thompson and Patricia Troncoso and Anne Tsao and {von Deimling}, Andreas and Han Liang",
year = "2018",
month = "4",
day = "5",
doi = "10.1016/j.cell.2018.03.027",
language = "English (US)",
volume = "173",
pages = "386--399.e12",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

AU - The Cancer Genome Atlas Research Network

AU - Chen, Han

AU - Chen, Han

AU - Peng, Xinxin

AU - Peng, Xinxin

AU - Weinstein, John N.

AU - Weinstein, John N

AU - Demchok, John A.

AU - Felau, Ina

AU - Kasapi, Melpomeni

AU - Ferguson, Martin L.

AU - Hutter, Carolyn M.

AU - Sofia, Heidi J.

AU - Tarnuzzer, Roy

AU - Wang, Zhining

AU - Yang, Liming

AU - Zenklusen, Jean C.

AU - Liu, Yuexin

AU - Akbani, Rehan

AU - Broom, Bradley McIntosh

AU - Kanchi, Rupa Sridevi

AU - Korkut, Anil

AU - Li, Jun

AU - Ling, Shiyun

AU - Lu, Yiling

AU - Mills, Gordon B

AU - Uppore Kukkillaya, Arvind Rao

AU - Liu, Xiuping

AU - Wang, Linghua

AU - Carvalho, André L.

AU - Fregnani, José Humberto T. G.

AU - Scapulatempo, Cristovam Neto

AU - Ajani, Jaffer A

AU - Behrens, Maria del Carmen

AU - Broaddus, Russell

AU - Czerniak, Bogdan A

AU - Esmaeli, Bita

AU - Fujimoto, Junya

AU - Gershenwald, Jeffrey E

AU - Lazar, Alexander

AU - Logothetis, Christopher J

AU - Meric-Bernstam, Funda

AU - Moran, Cesar

AU - Ramondetta, Lois M

AU - Sood, Anil K

AU - Tamboli, Pheroze

AU - Thompson, Timothy

AU - Troncoso, Patricia

AU - Tsao, Anne

AU - von Deimling, Andreas

AU - Liang, Han

PY - 2018/4/5

Y1 - 2018/4/5

N2 - The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples across 33 cancer types using TCGA RNA-seq data. Compared with matched normal tissues, global enhancer activation was observed in most cancers. Across cancer types, global enhancer activity was positively associated with aneuploidy, but not mutation load, suggesting a hypothesis centered on “chromatin-state” to explain their interplay. Integrating eQTL, mRNA co-expression, and Hi-C data analysis, we developed a computational method to infer causal enhancer-gene interactions, revealing enhancers of clinically actionable genes. Having identified an enhancer ∼140 kb downstream of PD-L1, a major immunotherapy target, we validated it experimentally. This study provides a systematic view of enhancer activity in diverse tumor contexts and suggests the clinical implications of enhancers. Causal enhancer-target-gene relationships are inferred from a systematic analysis of 33 cancer types.

AB - The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples across 33 cancer types using TCGA RNA-seq data. Compared with matched normal tissues, global enhancer activation was observed in most cancers. Across cancer types, global enhancer activity was positively associated with aneuploidy, but not mutation load, suggesting a hypothesis centered on “chromatin-state” to explain their interplay. Integrating eQTL, mRNA co-expression, and Hi-C data analysis, we developed a computational method to infer causal enhancer-gene interactions, revealing enhancers of clinically actionable genes. Having identified an enhancer ∼140 kb downstream of PD-L1, a major immunotherapy target, we validated it experimentally. This study provides a systematic view of enhancer activity in diverse tumor contexts and suggests the clinical implications of enhancers. Causal enhancer-target-gene relationships are inferred from a systematic analysis of 33 cancer types.

KW - PD-L1 expression

KW - The Cancer Genome Atlas

KW - aneuploidy

KW - chromatin state

KW - enhancer expression

KW - mutation burden

KW - pan-cancer analysis

KW - prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=85044921094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044921094&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.03.027

DO - 10.1016/j.cell.2018.03.027

M3 - Article

VL - 173

SP - 386-399.e12

JO - Cell

T2 - Cell

JF - Cell

SN - 0092-8674

IS - 2

ER -